- March 14, 2008
Cylene Pharmaceuticals Promotes Claire S. Padgett to Vice President of Clinical Operations
- January 28, 2008
Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
- July 10, 2007
Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations
- June 28, 2007
Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
- June 25, 2007
2007 ASCO Presentation
- January 31, 2007
Cylene Announces Issuance of Additional U.S. Patents Covering Lead Compound CX-3543, Strengthening Cylene’s Intellectual Property Position in rRNA Biogenesis Inhibition
- January 23, 2007
Cylene Pharmaceuticals Closes $44 Million Series C Financing
- June 29, 2006
Cylene Presents A Poster at the Annual ASCO Meeting in Atlanta
- April 21, 2006
Cylene Pharmaceuticals Appoints Stella M. Sung, Ph.D. As Chief Business Officer
- July 19, 2005
Cylene Pharmaceuticals Initiates Phase I Clinical Trial for CX-3543, a First-in-Class Agent for Multiple Cancers
- May 25, 2005
Cylene Pharmaceuticals Raises $26.3 Million in Series B Financing
- February 7, 2005
Cylene Pharmaceuticals Moves Headquarters and R&D Operations to State-of-the-Art San Diego Facility
- April 7, 2004
Cylene Pharmaceuticals Announces New Vice President of Clinical Operations
- October 15, 2003
Cyternex Appoints William G. Rice, Ph.D., as President and CEO and Announces Company Name Change to Cylene Pharmaceuticals
- October 17, 2001
Cyternex Raises $3.5 Million in Series A Finances
|
|
